Benzinga | Nov 17, 2020 08:07AM EST

Biocept To Present Results From Study Using Biocept's Target Selector Testing To Monitor Breast Cancer Dec. 9

SAN DIEGO, Nov. 17, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ:BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that results from a prospective study using Target Selector(tm) testing to monitor disease progression in patients with metastatic breast cancer will be featured in a poster presentation at the virtual 2020 San Antonio Breast Cancer Symposium(r) (SABCS) on December 9, 2020.